在康斯塔丁-M和OSM-受体中,MAPK的前激活会诱导可分离的干状和介酶体程序
Kelsey L Polak1, Ilaria Tamagno1, Neetha Parameswaran1
1Department of Pathology and Case Comprehensive Cancer Center, Case Western Reserve University Cleveland, Ohio.
昂哥斯塔丁-M (OSM) 通过激活MAPK信号来驱动胰腺癌干细胞和凝胺耐药性. 抑制这种OSM-OSMR-MAPK通路为侵袭性胰腺管腺癌 (PDAC) 提供了一种新的治疗策略.
科学领域:
- 分子瘤学分子瘤学
- 癌症生物学 癌症生物学
- 翻译研究是翻译研究.
背景情况:
- 胰腺管道腺癌 (PDAC) 往往表现为晚期转移性疾病和治疗反应不佳.
- 细胞因子Oncostatin-M (OSM) 促进PDAC可塑性,诱导与转移和治疗耐药性相关的茎状/介质细胞状态.
研究的目的:
- 研究OSM诱导PDAC干性,瘤启动和耐 gemcitabine 的独特机制.
- 为了在OSM信号通路中识别积极PDAC的治疗点.
主要方法:
- 通过使用OSM,ZEB1或SNAI1.1,诱导PDAC细胞进行上皮层-介质细胞过渡 (EMT).
- 对瘤发病的比较分析,对gemcitabine的耐药性和细胞表型.
- 转录基因分析以阐明OSM介导的干性通路,包括MAPK激活和OSMR转录.
- 抑制MEK和ERK以评估对OSM驱动的重编程和gemcitabine敏感性的影响.
主要成果:
- OSM 独特地促进了 PDAC 瘤启动和耐 gemcitabine 耐药性,独立于诱导 CD44HI/介质细胞表型.
- ZEB1和SNAI1诱导了EMT和迁移,但没有赋予瘤启动性或显著的凝抗药性.
- 通过OSM介导的干性需要MAPK激活和持续的,OSM受体 (OSMR) 的前转录.
- MEK和ERK抑制剂阻断了OSM驱动的基因转录和重编程,减少了瘤的生长,恢复了对gemcitabine的敏感性.
结论:
- OSM-OSMR-MAPK信号轴对于PDAC干状行为,瘤启动和治疗阻力至关重要.
- 针对OSM-OSMR-MAPK前循环,代表了对攻击性PDAC的新治疗策略.
- 小分子MAPK抑制剂在向OSM/OSMR轴方面表现有前途,有可能克服PDAC中的EMT和瘤启动性质.
更多相关视频
06:10Real-Time Imaging of CCL5-Induced Migration of Periosteal Skeletal Stem Cells in Mice
Published on: September 16, 2020
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
相关概念视频
MAPK Signaling Cascades
Mesenchymal Stem Cells
Stem Cell Niche
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
